Skip to Main Content

Paper Details

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Ann Oncol
1
2023
Cancer, DFCI, KEAP1, KEAP1 mutations, KEAP1 tumors, KEAP1/, KRAS, KRAS-mutant lung adenocarcinoma, KRAS-mutated tumors, LUAD, M1, M1 versus M0 tumors, MSKCC, NRF2, OS, Patients, SMARCA4, SMARCA4 mutations, STK11, lung adenocarcinoma, metastatic, metastatic disease, patients, tumors
Author NameAffiliation
Pasi A J??nneLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
Eliezer M Van AllenDana Farber Cancer Institute, Boston Broad Institute of Harvard & MIT, Cambridge Center for Cancer Precision Medicine, Dana-Farber Cancer Institute
Eliezer M Van AllenDana Farber Cancer Institute, Boston Broad Institute of Harvard & MIT, Cambridge Center for Cancer Precision Medicine, Dana-Farber Cancer Institute
  • 1 - 3

Datasets

Release 1.2